相关实验视频
Updated: May 20, 2025

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.0K
在LVAD植入后,尿液需求和右心力衰竭的关联
Dou Huang1, Philip Lacombe2, Gaurav Gulati3
1Department of Medicine, Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York.
JHLT open
|March 27, 2025
概括
在接受左心室辅助装置 (LVAD) 植入的高级心力衰竭患者中,较高的术前尿剂剂与早期右心力衰竭的风险增加有关. 这凸显了尿素耐药性在预测结果方面的重要性.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭管理的管理
- 医疗器械技术 医疗器械技术
背景情况:
- 利尿剂的反应性是心力衰竭进展的一个已知的因素.
- 患有晚期心力衰竭的患者往往表现出尿液反应降低,需要更高的剂量.
- 这项研究调查了在被评估为左心室辅助器件 (LVAD) 植入的患者中尿液需求和右心室功能障碍之间的联系.
研究的目的:
- 为了确定手术前更高的尿剂需求是否与渐进的右心室功能障碍相关.
- 评估利尿剂响应在接受LVAD评估的风险分层患者中的有用性.
- 检查术前尿剂剂量与早期右心衰竭 (RHF) 或LVAD植入后死亡之间的关联.
主要方法:
- 在2014年至2018年间对147名接受LVAD植入的患者进行了回顾性分析.
- 患者根据他们的24小时手术前的尿剂剂量被分为三层.
- 主要结局是早期RHF或在索引住院期间死亡.
主要成果:
- 早期RHF的发病率在高剂量利尿剂组 (66.0%) 与中剂量 (41.3%) 和低剂量组 (23.5%) 相比显著更高.
- 增加40毫克的静脉注射弗洛塞米德剂量与RHF风险增加6%有关,即使在调整其他风险因素后也是如此.
- 利尿剂剂量最高组的患者经历了更长的中位数ICU停留 (7 vs 5天).
结论:
- 较高的手术前利尿剂剂量与LVAD手术后早期右心力衰竭的风险增加有关.
- 这些发现支持了渐进的右心室功能障碍在心脏病和利尿剂耐药性中的作用.
- 利尿剂的需求可以作为一个有价值的标志物风险分层在高级心力衰竭患者考虑LVAD.
相关概念视频
Heart Failure Drugs: Diuretics
309
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
309
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
Heart Failure Drugs: Inotropic Agents
476
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
476

